Fei Yu

3.9k total citations · 2 hit papers
83 papers, 2.8k citations indexed

About

Fei Yu is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Fei Yu has authored 83 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Infectious Diseases, 34 papers in Virology and 34 papers in Epidemiology. Recurrent topics in Fei Yu's work include HIV Research and Treatment (34 papers), HIV/AIDS drug development and treatment (28 papers) and Influenza Virus Research Studies (15 papers). Fei Yu is often cited by papers focused on HIV Research and Treatment (34 papers), HIV/AIDS drug development and treatment (28 papers) and Influenza Virus Research Studies (15 papers). Fei Yu collaborates with scholars based in China, United States and Hong Kong. Fei Yu's co-authors include Shibo Jiang, Lanying Du, Lu Lu, Ruiying Liang, Chungen Pan, David M. Ojcius, Xiaoqian Deng, Lili Wang, Meng Su and Naru Zhang and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Fei Yu

75 papers receiving 2.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recent advances in the detection of respiratory virus infection in humans

2020 371 citations Lili Wang, Xiaoqian Deng et al. profile →
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

2014 317 citations Lu Lu, Yun Zhu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fei Yu China	26	1.7k	862	578	402	282	83	2.8k
Reed F. Johnson United States	29	2.1k 1.2×	778 0.9×	628 1.1×	310 0.8×	93 0.3×	85	3.2k
Mart M. Lamers Netherlands	25	2.4k 1.4×	572 0.7×	784 1.4×	203 0.5×	160 0.6×	51	3.6k
Markus Eickmann Germany	29	2.6k 1.5×	946 1.1×	571 1.0×	170 0.4×	271 1.0×	74	4.1k
Michael Letko United States	17	2.6k 1.5×	402 0.5×	534 0.9×	315 0.8×	169 0.6×	33	3.3k
Emma C. Thomson United Kingdom	22	2.9k 1.7×	828 1.0×	938 1.6×	155 0.4×	261 0.9×	90	4.0k
Weijin Huang China	30	3.4k 2.0×	737 0.9×	1.1k 1.8×	217 0.5×	214 0.8×	186	4.8k
Aiping Wu China	24	1.9k 1.1×	721 0.8×	1.3k 2.2×	155 0.4×	174 0.6×	125	3.8k
Jian Yu United States	29	2.6k 1.5×	488 0.6×	979 1.7×	442 1.1×	505 1.8×	60	3.8k
Jianhui Nie China	20	2.1k 1.2×	413 0.5×	667 1.2×	316 0.8×	179 0.6×	90	2.7k
Susanne Pfefferle Germany	24	2.4k 1.4×	392 0.5×	492 0.9×	157 0.4×	119 0.4×	63	3.2k

Countries citing papers authored by Fei Yu

Since Specialization

Citations

This map shows the geographic impact of Fei Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Yu more than expected).

Fields of papers citing papers by Fei Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Yu. The network helps show where Fei Yu may publish in the future.

Co-authorship network of co-authors of Fei Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Yu. A scholar is included among the top collaborators of Fei Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Yu. Fei Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Yue, Yanhe Zhang, Hongliang Zhang, et al.. (2025). A glycoprotein D-targeted lipid nanoparticle-encapsulated mRNA vaccine elicits strong protective immunity against pseudorabies virus. Journal of Virology. 99(11). e0147225–e0147225.

Wang, Xuan, Liang Zhou, Hongru Li, et al.. (2025). Targeting Matrix Metalloproteinase-9 to Alleviate T Cell Exhaustion and Improve Sepsis Prognosis. Research. 8. 996–996.

Wang, Chao, Yue Li, Huan Wang, et al.. (2021). Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection. Journal of Medicinal Chemistry. 65(4). 2809–2819. 13 indexed citations

Yu, Fei, Rong Xiang, Xiaoqian Deng, et al.. (2020). Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduction and Targeted Therapy. 5(1). 212–212. 77 indexed citations

Wang, Qian, Shan Su, Jing Xue, et al.. (2020). An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Science Translational Medicine. 12(546). 11 indexed citations

Wang, Lili, Zhengsen Yu, Rong Xiang, et al.. (2020). Influenza virus glycoprotein-reactive human monoclonal antibodies. Microbes and Infection. 22(6-7). 263–271. 10 indexed citations

Yu, Fei, Lanying Du, David M. Ojcius, Chungen Pan, & Shibo Jiang. (2020). Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes and Infection. 22(2). 74–79. 270 indexed citations

Zou, Qianda, Guoliang Xie, Fei Yu, et al.. (2019). Characterization of viral genomic mutations in novel influenza A (H7N9)-infected patients: the association between oseltamivir-resistant variants and viral shedding duration. Virus Genes. 55(5). 592–599. 1 indexed citations

Lu, Lu, Fei Yu, Ji‐Shen Zheng, et al.. (2016). A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41. Amino Acids. 48(12). 2867–2873. 11 indexed citations

10.

Cui, Dawei, Shuo Feng, Yu Chen, et al.. (2016). Clinical and Epidemiologic Characteristics of Hospitalized Patients with Laboratory-Confirmed Respiratory Syncytial Virus Infection in Eastern China between 2009 and 2013: A Retrospective Study. PLoS ONE. 11(11). e0165437–e0165437. 23 indexed citations

11.

Wang, Chao, Wenqing Lai, Fei Yu, et al.. (2015). De novo design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. Chemical Science. 6(11). 6505–6509. 14 indexed citations

12.

Lai, Wenqing, Chao Wang, Fei Yu, et al.. (2015). An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. Chemical Science. 7(3). 2145–2150. 14 indexed citations

13.

Li, Wen, Fei Yu, Qian Wang, et al.. (2015). Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles. AIDS. 30(6). 827–838. 28 indexed citations

14.

He, Biao, et al.. (2015). Putative suppressing effect of IgG Fc-conjugated haemagglutinin (HA) stalk of influenza virus H7N9 on the neutralizing immunogenicity of Fc-conjugated HA head: implication for rational design of HA-based influenza vaccines. Journal of General Virology. 97(2). 327–333. 6 indexed citations

15.

Wang, Chao, Weiguo Shi, Lifeng Cai, et al.. (2014). Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. Journal of Antimicrobial Chemotherapy. 69(6). 1537–1545. 15 indexed citations

16.

Li, Minmin, Jiayin Qiu, Fei Yu, et al.. (2013). 3-Hydroxyphthalic Anhydride-Modified Human Serum Albumin as a Microbicide Candidate Against HIV Type 1 Entry by Targeting Both Viral Envelope Glycoprotein gp120 and Cellular Receptor CD4. AIDS Research and Human Retroviruses. 29(11). 1455–1464. 7 indexed citations

17.

Zhao, Guangyu, Lanying Du, Cuiqing Ma, et al.. (2013). A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virology Journal. 10(1). 266–266. 111 indexed citations

18.

Lu, Lu, Yanxia Chen, Fei Yu, et al.. (2013). F(ab′)2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. Microbes and Infection. 15(13). 887–894. 3 indexed citations

19.

Yu, Fei. (2001). Characteristics of inferior variation of water environment in Hutuohe River dried-up area. 2 indexed citations

20.

Sutliff, V. E., John L. Doppman, Fathia Gibril, et al.. (1997). Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.. Journal of Clinical Oncology. 15(6). 2420–2431. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact